INTRODUCTION AND OBJECTIVES: Benign prostatic hyperplasia (BPH) is a major public health problem with high morbidity and associated cost. BPH arises in the context well recognized comorbidities including metabolic syndrome (MetS), obesity and diabetes. Animal models do not reflect all aspects of the human disease. Recently, an animal model, leptin-deficient obese ObOb mice has been reported that mimics the features of MetS and prostatic hyperplasia. However, details of the linkage between MetS/obesity and prostatic hyperplasia remain unknown in this model. To assess the relationship between MetS/obesity and prostatic hyperplasia in ObOb mice, we evaluated the morphological phenotype of control and leptin-treated ObOb mice prostate.
INTRODUCTION AND OBJECTIVES: Benign prostatic hyperplasia (BPH) is a major public health problem with high morbidity and associated cost. BPH arises in the context well recognized comorbidities including metabolic syndrome (MetS), obesity and diabetes. Animal models do not reflect all aspects of the human disease. Recently, an animal model, leptin-deficient obese ObOb mice has been reported that mimics the features of MetS and prostatic hyperplasia. However, details of the linkage between MetS/obesity and prostatic hyperplasia remain unknown in this model. To assess the relationship between MetS/obesity and prostatic hyperplasia in ObOb mice, we evaluated the morphological phenotype of control and leptin-treated ObOb mice prostate.
METHODS: We started with 10-week-old male ObOb and strain-matched control mice. Three groups were examined: lean C57/Bl/ 6J (strain-matched control), non-treated ObOb, and leptin-treated ObOb mice. Leptin was delivered using a subcutaneous Alzet micro-osmotic pump. Leptin was delivered 5 mg/day for the initial 12 weeks of the study, and at 10 mg/day for the final 12 weeks. The liver, pancreas, spleen, skin, femoral muscle, subcutaneous fat, visceral fat, periprostatic fat, brown fat, and urogenital organs were harvested for analysis.
RESULTS: In ObOb mice, total body weight and liver weight were reduced 25%-35% by leptin treatment. Leptin supplementation dramatically reduced body weight during the first month, but weight then increased slowly. Non-fasting serum blood glucose levels were normal range ( 250mg/dl) in all ObOb mice, but a glucose tolerance test revealed significantly longer recoveries in non-treated vs. leptin-treated ObOb mice. Compared to non-treated ObOb mice, liver weight of leptintreated ObOb mice is significant lighter but still heavier than lean C57/ Bl/6J mice. Anterior, ventral, and dorsolateral prostate glands in nontreated ObOb mice exhibited epithelial hyperplasia compared to lean C57/Bl/6J mice. In the leptin-treated mice, the number of hyperplastic prostate glands in each lobe was significant lower than in non-treated ObOb mice.
CONCLUSIONS: Our results demonstrated that long-term leptin treatment results in a reduction in prostatic epithelial hyperplasia in the ObOb mouse model. Full characterization of this animal model may elucidate molecular mechanisms linking MetS/obesity and prostatic hyperplasia.
Source of Funding: 1R01 DK103483-01

MP17-16 METFORMIN INHIBITS BENIGN PROSTATIC EPITHELIAL CELLS THROUGH SUPPRESSION OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR
Zongwei Wang*, Xingyuan Xiao, Rongbin Ge, Jijun Li, Cameron Johnson, Cyrus Rassoulian, Aria Olumi, Boston, MA INTRODUCTION AND OBJECTIVES: Benign prostatic hyperplasia (BPH) is the most common, proliferative abnormality of the prostate affecting elderly men throughout the world. Epidemiologic studies have shown that diabetes significantly increases the risk of developing lower urinary symptoms, some of which may be related to bladder outlet obstruction. It is unclear whether anti-diabetic medications may prevent progression of lower urinary tract symptoms. We have previously found that stromally expressed insulin-like growth factor 1 (IGF-1) promotes benign prostatic epithelial (BPE) cell proliferation through paracrine mechanisms. Here, we seek to understand if metformin, a first line medication for the treatment of type-2 diabetes, inhibits the proliferation of BPE cells through reducing the expression of IGF-1 receptor (IGF-1R) and the adjustment of the cell cycle.
METHODS: BPE cell lines (BPH-1 and P69) and a stromal cell line (3T3) were cultured and tested in this study. Cell proliferation and the cell cycle were analyzed by MTS assay and flow cytometry, respectively. The expression of IGF-1 receptor was determined by western-blot and immunocytochemistry. The levels of IGF-1 secretion in a culture medium were measured by ELISA.
RESULTS: Metformin (0.5-10mM, 6-48h) significantly inhibited the proliferation of BPH-1 and P69 cells in a dose-dependent and timedependent manner without inducing apoptosis. Treatment with metformin for 24 hours lowered the G2/M cell population by 43.24% in P69 cells and 24.22% in BPH-1 cells. On the other hand, IGF-1 (100ng/ml, 24h) stimulated the cell proliferation (increased by 28.81% in P69 cells and 20.95% in BPH-1 cells) and significantly enhanced the expression of IGF-1R in BPE cells. Metformin (5mM) abrogated the proliferative effect of IGF-1 on BPE cells. In 3T3 cells, the secretion of IGF-1 was drastically inhibited by metformin from 574.31pg/ml to 197.61pg/ml. A conditioned medium of 3T3 cells promoted the proliferation and expression of IGF-1R in BPH-1 and P69 cells. Similarly, metformin abrogated the ability of a 3T3 conditioned medium to promote proliferation of BPE cells.
CONCLUSIONS: Our study demonstrates that metformin inhibits the proliferation of BPE cells by suppressing the expression of IGF-1R. Metformin may have a protective role in prostatic proliferation by inhibition of IGF-1R.
Source of Funding: NIH/R01 DK091353
MP17-17 EFFECT OF AGENT ORANGE EXPOSURE ON THE DEVELOPMENT OF BENIGN PROSTATIC ENLARGEMENT
Daniel Sackman*, Wesley Stoller, Laura Peters, Jackilen Shannon, Mark Garzotto, Portland, OR INTRODUCTION AND OBJECTIVES: Agent Orange exposure (AOe) has been demonstrated to be associated with an increased risk of prostate cancer (CaP). However, it is unknown whether AOe also increases the development of benign prostatic enlargement (BPE). The objective of this study was to determine the association between AOe and BPE by evaluating prostate volume in a US Veteran Cohort.
METHODS: Risk factors including clinic-demographic and laboratory data from veterans who had undergone a initial prostate biopsy that was negative for cancer detection were collected. The primary outcome was the calculated prostate volume as determined by transrectal US. Prostate volume of AOe veterans relative to unexposed veterans was compared using univariate and multivariate logistic regression. Patient age, AOe, maximum PSA prior to biopsy, and BMI were included in the multivariate analysis.
RESULTS: Of 1821 veterans undergoing an initial negative prostate biopsy 7% (129) had documented AOe. Age, BMI and maximum PSA were all significantly correlated with increasing prostate volume (p¼<0.01 for each). On univariate and multivariate analysis there was no significant association between AOe and prostate volume as measured by US.
CONCLUSIONS: These results indicate AOe is not associated with an increase in prostate volume in a US veteran cohort undergoing an initial negative prostate biopsy. Despite its relationship with malignant growth of the prostate, AOe does not appear to be associated with BPE. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e217
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